ReviewNature reviews. Molecular cell biology2016
A decade of transcription factor-mediated reprogramming to pluripotency.
Review in Nature reviews. Molecular cell biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 493 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
493 citing papers in PubMed, 872 citations in OpenAlex.
- Opportunities and challenges for cancer immunotherapy based on antigen cross-presentation.Annals of medicine · 2026Review
- PUS7 pseudouridylation of 7SK orchestrates human somatic cell reprogramming into iPS cells.Nature chemical biology · 2026Article
- Integrating delivery systems and microenvironmental cues to accelerate clinical translation of cardiac reprogramming.Materials today. Bio · 2026Review
- From Primary Cells to Organoids: Expanding the Biological Relevance of In Vitro Cellular Models.Cells · 2026Review
- CRISPRa-identified transcription factors reprogram glioblastoma into dendritic cell-like cells to elicit systemic antitumor immunity.Cell reports. Medicine · 2026Article
- Suidae iPSC-derived macrophages as models for investigating susceptibility and resilience to African swine fever virus.Stem cell reports · 2026Article
- The SynMuvA lin-15A licenses natural transdifferentiation by antagonizing identity safeguarding mechanisms.PLoS genetics · 2026Article
- Inner Ear Organoids: Recent Progress and Challenges.Stem cell reviews and reports · 2026Review
- Mesenchymal Stromal Cell-Derived Extracellular Vesicles Mediate Mitochondrial Delivery in Injury: Mechanistic Insights, Evidentiary Tiers, and Translational Challenges.Stem cell reviews and reports · 2026Review
- Cellular senescence and aging: molecular mechanisms and convergent pathways.Cellular and molecular life sciences : CMLS · 2026Review
- Sulforaphane Enhances the Generation of Mouse Induced Pluripotent Stem Cells.Stem cell reviews and reports · 2026Article
- Review
- Expression-linked promoter selection (ELiPS) engineers short, strong ubiquitous promoters for gene therapy applications.bioRxiv : the preprint server for biology · 2026Article
- L1CAM signaling through planar cell polarity drives SOX2 expression and lung adenocarcinoma metastasis.Nature communications · 2026Article
- Transcription clusters and developmental pathways - nature, nurture, noise.Journal of cell science · 2026Review
- Bridging population and cell: modelling complex diseases with human induced pluripotent stem cells.European journal of human genetics : EJHG · 2026Review
- Harnessing Lessons from Gel-Based and Advanced Biomaterial Therapeutics to Enable Direct Cellular Reprogramming.Gels (Basel, Switzerland) · 2026Review
- iPS cells: history made and history in the making.Nature methods · 2026Article
- YY1-induced upregulation of DLGAP5 promotes tumor progression in lung adenocarcinoma via Wnt/β-catenin/EMT pathway.Journal of translational medicine · 2026Article
- Enhanced P-TEFb activity compromises dentate gyrus neurogenesis in mice.The EMBO journal · 2026Article
433 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past 10 years have seen great advances in our ability to manipulate cell fate, including the induction of pluripotency in vitro to generate induced pluripotent stem cells (iPSCs). This process proved to be remarkably simple from a technical perspective, only needing the host cell and a defined cocktail of transcription factors, with four factors - octamer-binding protein 3/4 (OCT3/4), SOX2, Krüppel-like factor 4 (KLF4) and MYC (collectively referred to as OSKM) - initially used. The mechanisms underlying transcription factor-mediated reprogramming are still poorly understood; however, several mechanistic insights have recently been obtained. Recent years have also brought significant progress in increasing the efficiency of this technique, making it more amenable to applications in the fields of regenerative medicine, disease modelling and drug discovery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.